Please ensure Javascript is enabled for purposes of website accessibility

Is a Potential Patent Waiver Bad News for Moderna?

By Adria Cimino - Updated Jun 23, 2021 at 8:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Several ingredients are needed to make a successful vaccine...

Countries recently have discussed the possibility of waiving rights to vaccine patents during the pandemic. Their goal is to lift vaccine production and make vaccines more widely available. In this Motley Fool Live video recorded on May 28, 2021, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss whether a potential patent waiver might cut into sales of Moderna's (MRNA -0.37%) coronavirus vaccine.

Olivia Zitkus: My next question has to do with patent rights, which has been a hot topic lately. Some countries including the U.S. are thinking about backing the idea of waving COVID vaccine patent rights during the pandemic, which understandably makes some investors in these companies a little bit nervous. What's happening here, do you think this represents a big threat to Moderna, if it were to lose its patent rights?

Adria Cimino: Well, actually no. I'll explain. It's really that this situation just concerns the patent. And this opens up the possibility of another company to come in and produce the Moderna vaccine. But there's more to it than that. It's like if someone were to give you instructions for how to build a rocket, and you would need the trained workers, you would need the facilities, you need the machines, and you'd have to test the rocket. You'd have to do all of these things that you couldn't do without all of these parts. The situation today is, especially since the Moderna vaccine is something new -- an mRNA vaccine -- is that there really aren't other players out there who can just say, "O.K., here we go, we've got the facilities, we've got the machines, we've got the trained workers." That doesn't exist right now. It would be really impossible to just have something come out right away. It really isn't a threat. It isn't a threat. There isn't going to be another company that can do this. In fact, Moderna even said last year that they wouldn't enforce their patents during the pandemic. Clearly, they are aware of the situation that they are the only one that can do their vaccine right now, and we have to remember that Moderna themselves, it wasn't an overnight thing. They've been working on this technology for years. People who've been working on it are there, and they're trained. It's not something that just overnight someone could get done. Really it doesn't represent a threat to them. The only thing that is just negative overall for the industry if you just look at the issue, is the idea that it sets a precedent for, well, maybe if they end up doing this, then maybe in the future for something else that could easily be reproduced, they could do the same thing. Then some other competitor could go out there in a month produce this pill or this product. But for Moderna and this particular product, it really is not an issue for them, and so for investors, it really shouldn't represent an issue, either.

Adria Cimino has no position in any of the stocks mentioned. Olivia Zitkus owns shares of Moderna Inc. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$171.18 (-0.37%) $0.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.